Full analysis of the usage and dosage in the instructions for Avonib (Tosovo) tablets

Ivosidenib (Ivosidenib) is an oral small molecule targeted drug. The standard usage recommended by its instructions is oral administration once a day. The common dosage is 500 mg. It should be taken at a fixed time every day. It can be taken with a meal or on an empty stomach. The tablet should be swallowed whole and should not be broken, crushed or chewed. This dosage regimen is mainly suitable for patients with acute myeloid leukemia and cholangiocarcinoma who carry IDH1 mutations. It emphasizes continuous and regular administration to maintain stable blood concentration.

In terms of treatment schedule, ivonib usually adopts a continuous dosing mode rather than a periodic drug withdrawal schedule. The instructions recommend that patients continue taking the medication at least until clear disease progression occurs or intolerable adverse reactions occur. For patients with hematological tumors, especially in the early stages of treatment, it may take several months of continuous use to observe a more stable effect. Therefore, it is not recommended to stop taking the drug prematurely or adjust the course of treatment on your own.

For dose adjustment in special circumstances, the instructions clearly state that when a patient experiences drug-related adverse reactions of grade ≥ 3, the drug can be temporarily discontinued according to the clinical situation, and the drug can be resumed after the symptoms are relieved. If necessary, the drug can be adjusted to a lower dose to continue treatment. At the same time, for patients with moderate to severe liver function abnormalities or who need to be combined with potent CYP3A4 inhibitors, they should carefully evaluate whether dose adjustment is needed under the guidance of a doctor.

In terms of medication monitoring, the instructions for ivonib specifically emphasize the need to closely observe differentiation syndrome, electrocardiogramQT interval prolongation and liver function changes in the early stage of treatment. It is recommended to conduct regular blood routine, electrolyte and electrocardiogram examinations during the initial treatment and dose adjustment stage. Overall, the usage and dosage of ivonib is designed with long-term oral administration and sustained target inhibition as the core. Standardized administration and dynamic monitoring are the keys to ensuring efficacy and safety.

Keyword tags: ivonib, usage and dosage, IDH1 mutation, acute myeloid leukemia, cholangiocarcinoma, oral administration, continuous medication, dose adjustment, differentiation syndrome, QT interval prolongation, liver function monitoring.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/?term=ivosidenib